CD Skripsi
Analisis Ekspresi Gen Rad51 Pada Kanker Endometrium
Endometrial cancer is one of the most common gynecological malignancies, with a steadily increasing incidence worldwide. This cancer is characterized by the accumulation of unrepaired DNA damage that leads to genomic instability. One of the key pathways maintaining genomic stability is the homologous recombination repair (HRR) mechanism, in which the RAD51 gene plays a central role in repairing double-strand breaks. Dysregulation of RAD51 expression can result in defective DNA repair, genomic instability, and an increased tendency for malignant transformation. Therefore, altered RAD51 expression is suspected to contribute to the aggressiveness of endometrial cancer. This study aimed to analyze the association between RAD51 gene expression and endometrial cancer (histological grade, stage, and overall survival), as well as to describe the clinical profile of patients. Patient data were obtained from the UCSC Xena and cBioPortal databases using a total sampling technique. A total of 545 endometrial cancer samples were analyze. Most cases occurred in patients aged 61–70 years, early-stage disease, high histological grade, and copy number low (CNL) molecular subtype. The expression level of RAD51 was significantly higher in endometrial cancer tissues compared to normal endometrial tissues (p < 0.05) and associated with advanced stage, high histological grade, histopatological type, and moleculer classification. Patients with low RAD51 expression had better overall survival (79%) compared to those with high expression levels (74%). Elevated RAD51 gene expression is significantly associated with advanced stage and high histological grade of endometrial cancer, suggesting its potential role as a prognostic biomarker and therapeutic target in endometrial cancer.
Keywords: Endometrial cancer, RAD51 gene expression, histological grade, stage, overall survival
Tidak tersedia versi lain